Share
.webp)
.webp)
.webp)
.webp)
Niti Goel
HotSpot Therapeutics, Inc., a biotechnology company pioneering oral, allosteric small molecules that target natural regulatory pockets, has appointed Niti Goel, M.D., as Chief Medical Officer.
Dr. Goel is a board-certified rheumatologist and physician-scientist with more than 25 years of experience spanning global pharmaceutical and biotechnology companies, contract research organizations, academic medicine, and strategy consulting. Before joining HotSpot, she held senior leadership positions at TrialSpark (now Formation Bio), Abcuro, Kezar Life Sciences, and IQVIA. Earlier in her career, she held various roles at Array BioPharma, UCB Pharma, and Procter & Gamble Pharmaceuticals.
Dr. Goel is also an Adjunct Assistant Professor at Duke University School of Medicine, where she precepts trainees in the rheumatology clinic at the Durham Veterans Administration Hospital. She has authored numerous peer-reviewed scientific publications.
She earned her M.D. degree summa cum laude from Jefferson Medical College of Thomas Jefferson University and her bachelor’s degree from Pennsylvania State University. She completed her internal medicine and rheumatology training at Duke University Medical Center.
Alongside the appointment, HotSpot Therapeutics announced the nomination of HST-2011 as the Development Candidate for its IRF5 inhibitor program. HST-2011 is a potent and selective small molecule inhibitor of interferon regulatory factor 5 (IRF5), a transcription factor that plays a central role in regulating innate immunity.
HotSpot developed HST-2011 using its proprietary Smart Allostery™ platform. The company is targeting IRF5 based on evidence linking the regulator to inflammatory and immune disorders, including systemic lupus erythematosus, Sjögren’s disease, rheumatoid arthritis, systemic sclerosis, and myositis.
